Balicatib (AAE581) is a potent, orally active and selective cathepsin K inhibitor with IC50 values of 22, 61, 48, 2900 nM for cathepsin K, cathepsin B, cathepsin L, cathepsin S, respectively. Balicatib inhibits bone turnover, decreases bone formation rates. Balicatib has the potential for the research of osteoporosis[1][2].
Balicatib (0-10 µM) shows less than 1.5-fold accumulation of Type I collagen at concentrations up to 10 µM in human dermal fibroblasts[2].
Balicatib (0, 3, 10, 50 mg/kg; Oral gavage; twice daily for 18 months) partially prevented ovariectomyinduced changes in bone mass, inhibited bone turnover at most sites, and had an stimulatory effect on periosteal bone formation in cynomolgus monkeys[1].
关键字： 354813-19-7;
广州优南科技有限公司，是一家集研发、生产、销售于一体的高新技术企业，为全球生物医药企业、高校及科研院提供生命科学研究的产品与服务。
优南拥有自主研发的品牌ULS，为客户提供超过50000的工具化合物(小分子抑制剂/激动剂、标准品/对照品、荧光标记染料及探针)、医药原料及中间体、新型材料。